8-KLeadership ChangesExhibits & Filings

UNITEDHEALTH GROUP INC 8-K Report, Executive Changes (Nov 12, 2014)

Filed November 12, 2014For Securities:UNH

Summary

UnitedHealth Group Inc. (UNH) filed an 8-K report on November 12, 2014, detailing significant executive leadership changes. The most notable is the appointment of David S. Wichmann to President, while retaining his role as Chief Financial Officer. This promotion positions Mr. Wichmann, who has extensive experience within the company, including leading operations and finance, for potentially greater responsibilities. Additionally, Larry C. Renfro has been appointed Vice Chairman, continuing his leadership of Optum. These changes are accompanied by the departure of Gail K. Boudreaux, Executive Vice President and CEO of UnitedHealthcare, who will leave the company on February 27, 2015, after fulfilling her transition duties. The report indicates she will receive severance and continue to vest in equity awards as per her separation agreement, which includes non-compete and non-solicitation clauses.

Key Highlights

  • 1David S. Wichmann appointed President and will continue as Chief Financial Officer.
  • 2Larry C. Renfro appointed Vice Chairman and will continue as CEO of Optum.
  • 3Stephen J. Hemsley remains Chief Executive Officer.
  • 4Gail K. Boudreaux, EVP and CEO of UnitedHealthcare, will depart the company effective February 27, 2015.
  • 5Ms. Boudreaux will receive severance and her equity awards will continue to vest.
  • 6Ms. Boudreaux's separation agreement includes standard non-compete and non-solicit provisions.

Frequently Asked Questions

David S. Wichmann's appointment as President, in addition to his CFO role, signals increased responsibility and potentially positions him as a key successor for top leadership positions within UnitedHealth Group. His prior experience in operations and finance makes him a strong candidate for strategic leadership.

Gail K. Boudreaux is leaving UnitedHealth Group on February 27, 2015, after serving as EVP and CEO of UnitedHealthcare. She will receive cash severance over two years, and her previously granted equity awards will continue to vest during this period, as per her separation agreement. This agreement also includes standard two-year non-compete and non-solicitation clauses.

While the report focuses on the personnel changes, the promotion of David S. Wichmann to President, coupled with his continued role as CFO and extensive operational experience, suggests a focus on integrated financial and operational management. Larry C. Renfro's continued leadership of Optum indicates ongoing strategic importance of this segment. Ms. Boudreaux's departure from UnitedHealthcare may lead to a restructuring or reassignment of leadership within that division.

Larry C. Renfro has been appointed Vice Chairman of UnitedHealth Group and will continue in his role as Chief Executive Officer of Optum. This dual role emphasizes the strategic importance of Optum and his continued influence at the group level.